News & Insights Search

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.

Top US Food and Drug Administration (FDA) officials said the agency is open to novel, “innovative approaches” to the clinical development of psychedelic drugs in light of the worsening mental health crisis in the US.

The European Medicines Agency (EMA) has updated a guideline on good pharmacovigilance practice (GVP) inspections to reflect changes to the rules on subcontractors.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

RAPS Convergence is where the world’s regulatory affairs community gathers to share expert insights and create meaningful connections. We’re talking to the speakers behind this year’s event to get the inside scoop on the topics everyone will be talking about and their tips for making the most of your week. Next up: Sujith Kallur Mallikarjuna, associate director, regulatory affairs at BD.

The US Food and Drug Administration (FDA) has announced the permanent appointment of four top officials to lead the agency's drug, biologics, and tobacco centers, as well as a deputy commissioner for technology and artificial intelligence. The three product center directors were previously serving in those roles in an acting capacity.

The European Medicines Agency (EMA) has published a guidance on how companies submitting marketing authorization applications (MAA) should provide electronic product information (ePI) for products under the EU's centrally authorized review process. The agency noted that submitting ePI is voluntary until the general pharmaceutical legislation fully goes into effect.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

RAPS Convergence is where the world’s regulatory affairs community gathers to share expert insights and create meaningful connections. We’re talking to the speakers behind this year’s event to get the inside scoop on the topics everyone will be talking about and their tips for making the most of your week. Next up: Lisa Wright, director of regulatory policy at Novo Nordisk.